구조모아 (StructureMoa)항암 chemical structure spider web
방문향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 14건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Ramucirumab | Phase 3 | Recruiting | Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants | 신뢰 높음 | NCT06346392 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 3 | Active, not recruiting | Number of participants with Grade 3 or 4 possibly related adverse event (PRAE) | 신뢰 높음 | NCT05771480 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 1 | Active, not recruiting | Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy. | 보통 | NCT03228537 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 1 | Active, not recruiting | Number (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone | 보통 | NCT03816332 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 2 | Active, not recruiting | Progression-free Survival | 신뢰 높음 | NCT03775486 |
| 2026년 9월 | Opdivo (nivolumab) | N/A | Active, not recruiting | Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS) | 신뢰 높음 | NCT04603248 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 2 | Active, not recruiting | number of patients with a response | 신뢰 높음 | NCT03282344 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Number of patients who experience complete or partial tumor response | 신뢰 높음 | NCT03526432 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 2 | Recruiting | Number of Patients with a Pathologic Response | 보통 | NCT04933903 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Failure-free Rate at 2 Years | 보통 | NCT04262154 |
| 2026년 9월 | Ramucirumab | Phase 2 | Recruiting | To estimate overall response rate | 신뢰 높음 | NCT04332367 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 3 | Active, not recruiting | Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs); Objective response rate (ORR) | 신뢰 높음 | NCT05883644 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 1 | Active, not recruiting | Incidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients | 보통 | NCT02914405 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 2 | Recruiting | Progression free survival (PFS) | 신뢰 높음 | NCT04892953 |
Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants
NCT06346392Number of participants with Grade 3 or 4 possibly related adverse event (PRAE)
NCT05771480Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.
NCT03228537Number (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone
NCT03816332Progression-free Survival
NCT03775486Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS)
NCT04603248number of patients with a response
NCT03282344Number of patients who experience complete or partial tumor response
NCT03526432Number of Patients with a Pathologic Response
NCT04933903Failure-free Rate at 2 Years
NCT04262154To estimate overall response rate
NCT04332367Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs); Objective response rate (ORR)
NCT05883644Incidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients
NCT02914405Progression free survival (PFS)
NCT04892953향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 14건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Ramucirumab | Phase 3 | Recruiting | Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants | 신뢰 높음 | NCT06346392 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 3 | Active, not recruiting | Number of participants with Grade 3 or 4 possibly related adverse event (PRAE) | 신뢰 높음 | NCT05771480 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 1 | Active, not recruiting | Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy. | 보통 | NCT03228537 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 1 | Active, not recruiting | Number (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone | 보통 | NCT03816332 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 2 | Active, not recruiting | Progression-free Survival | 신뢰 높음 | NCT03775486 |
| 2026년 9월 | Opdivo (nivolumab) | N/A | Active, not recruiting | Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS) | 신뢰 높음 | NCT04603248 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 2 | Active, not recruiting | number of patients with a response | 신뢰 높음 | NCT03282344 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Number of patients who experience complete or partial tumor response | 신뢰 높음 | NCT03526432 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 2 | Recruiting | Number of Patients with a Pathologic Response | 보통 | NCT04933903 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Failure-free Rate at 2 Years | 보통 | NCT04262154 |
| 2026년 9월 | Ramucirumab | Phase 2 | Recruiting | To estimate overall response rate | 신뢰 높음 | NCT04332367 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 3 | Active, not recruiting | Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs); Objective response rate (ORR) | 신뢰 높음 | NCT05883644 |
| 2026년 9월 | Opdivo (nivolumab) | Phase 1 | Active, not recruiting | Incidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients | 보통 | NCT02914405 |
| 2026년 9월 | Imfinzi (durvalumab) | Phase 2 | Recruiting | Progression free survival (PFS) | 신뢰 높음 | NCT04892953 |
Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants
NCT06346392Number of participants with Grade 3 or 4 possibly related adverse event (PRAE)
NCT05771480Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.
NCT03228537Number (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone
NCT03816332Progression-free Survival
NCT03775486Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS)
NCT04603248number of patients with a response
NCT03282344Number of patients who experience complete or partial tumor response
NCT03526432Number of Patients with a Pathologic Response
NCT04933903Failure-free Rate at 2 Years
NCT04262154To estimate overall response rate
NCT04332367Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs); Objective response rate (ORR)
NCT05883644Incidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients
NCT02914405Progression free survival (PFS)
NCT04892953